A model for the study of experimentally induced temporomandibular arthritis in rats: the effect of human recombinant interleukin-1 alpha on neuropeptide-like immunoreactivity.
To study the interaction between human recombinant interleukin-1 alpha and the nervous system, substance P-, neurokinin A-, calcitonin gene-related peptide-, and neuropeptide Y-like immunoreactivity in the cerebrospinal fluid, plasma, and temporomandibular joint (TMJ) perfusates of rats during acute experimental monarthritis were examined. The right TMJs of the experimental rats were injected with 0.01 mL of human recombinant interleukin-1 alpha. The right TMJs of control rats were injected with 0.01 mL of saline. Cerebrospinal fluid, plasma, and perfusates from the right TMJs were obtained at 2, 6, and 24 hours following injection, and neuropeptide-like immunoreactivity was analyzed by specific radioimmunoassays. Values of neuropeptide-like immunoreactivity for the experimental rats were compared with those of the control rats. In the experimental group, substance P-, neurokinin A-, and calcitonin gene-related peptide-like immunoreactivities were increased in cerebrospinal fluid compared to those of the control group. In plasma, no changes in neuropeptide-like immunoreactivities rose significantly in the TMJ perfusates. Most pronounced changes in neuropeptide Y-like immunoreactivity occurred intra-articularly in the TMJ perfusates. The results indicate that the contribution of the nervous system to human recombinant interleukin-1 alpha-induced monarthritis is most pronounced in the affected joint.
Carleson
J
J
Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
Alstergren
P
P
Appelgren
A
A
Appelgren
B
B
Kopp
S
S
Theodorsson
E
E
Lundeberg
T
T
D000818:Animals; D001168:Arthritis / Q000139:chemically induced / Q000276:immunology* / Q000378:metabolism; D015740:Calcitonin Gene-Related Peptide / Q000032:analysis / Q000502:physiology; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D008297:Male; D015213:Neuroimmunomodulation / Q000187:drug effects / Q000502:physiology*; D015288:Neurokinin A / Q000032:analysis / Q000502:physiology; D009478:Neuropeptide Y / Q000032:analysis / Q000502:physiology; D009479:Neuropeptides / Q000032:analysis / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D013373:Substance P / Q000032:analysis / Q000502:physiology; D013582:Synovial Fluid / Q000737:chemistry; D013704:Temporomandibular Joint / Q000187:drug effects / Q000276:immunology; D013705:Temporomandibular Joint Disorders / Q000139:chemically induced / Q000276:immunology* / Q000378:metabolism
D007375:Interleukin-1; D009478:Neuropeptide Y; D009479:Neuropeptides; D011994:Recombinant Proteins; D013373:Substance P; D015288:Neurokinin A; D015740:Calcitonin Gene-Related Peptide